$MGTX
MeiraGTx Holdings plc

2023 Q4 Form 10-Q Financial Statement

#000155837023018916 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.040M $5.103M
YoY Change -87.19% 5.96%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.12M $10.01M
YoY Change -73.95% -6.99%
% of Gross Profit
Research & Development $33.67M $27.86M
YoY Change -60.72% 65.2%
% of Gross Profit
Depreciation & Amortization $3.912M $3.480M
YoY Change 56.98% 71.6%
% of Gross Profit
Operating Expenses $45.79M $37.87M
YoY Change -65.38% 37.07%
Operating Profit -$32.76M
YoY Change 43.64%
Interest Expense $9.362M $3.381M
YoY Change -169.59% 78.7%
% of Operating Profit
Other Income/Expense, Net $399.0K -$40.00K
YoY Change 106.74% -46.67%
Pretax Income $20.22M -$44.30M
YoY Change -115.6% 18.82%
Income Tax $0.00
% Of Pretax Income
Net Earnings $20.22M -$44.30M
YoY Change -115.6% 18.81%
Net Earnings / Revenue 990.93% -868.06%
Basic Earnings Per Share -$0.74
Diluted Earnings Per Share $0.32 -$0.74
COMMON SHARES
Basic Shares Outstanding 63.60M 59.54M
Diluted Shares Outstanding 59.53M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.6M $63.40M
YoY Change 12.16% -44.73%
Cash & Equivalents $129.6M $63.37M
Short-Term Investments
Other Short-Term Assets $6.641M $758.0K
YoY Change 298.38% -51.44%
Inventory
Prepaid Expenses $5.625M $6.997M
Receivables $10.14M $22.40M
Other Receivables $13.28M $10.00M
Total Short-Term Assets $159.6M $103.5M
YoY Change 3.42% -33.22%
LONG-TERM ASSETS
Property, Plant & Equipment $156.2M $111.9M
YoY Change 42.99% 19.5%
Goodwill
YoY Change
Intangibles $1.118M $1.140M
YoY Change -16.25% -11.83%
Long-Term Investments $6.766M $6.326M
YoY Change 6.96% -4.96%
Other Assets $3.000M $1.421M
YoY Change 113.98% 7.49%
Total Long-Term Assets $167.1M $163.7M
YoY Change 1.97% 11.81%
TOTAL ASSETS
Total Short-Term Assets $159.6M $103.5M
Total Long-Term Assets $167.1M $163.7M
Total Assets $326.7M $267.2M
YoY Change 2.67% -11.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.04M $20.77M
YoY Change -3.45% -4.24%
Accrued Expenses $46.83M $28.25M
YoY Change 17.62% 14.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.08M $63.51M
YoY Change -18.27% -12.23%
LONG-TERM LIABILITIES
Long-Term Debt $72.12M $71.80M
YoY Change 1.53% 1.35%
Other Long-Term Liabilities $49.37M $39.80M
YoY Change 4.58% 12.55%
Total Long-Term Liabilities $121.5M $111.6M
YoY Change 2.75% 5.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.08M $63.51M
Total Long-Term Liabilities $121.5M $111.6M
Total Liabilities $188.6M $175.3M
YoY Change -5.95% -1.92%
SHAREHOLDERS EQUITY
Retained Earnings -$554.2M -$574.4M
YoY Change 17.86% 29.69%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $138.2M $91.89M
YoY Change
Total Liabilities & Shareholders Equity $326.7M $267.2M
YoY Change 2.67% -11.35%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $20.22M -$44.30M
YoY Change -115.6% 18.81%
Depreciation, Depletion And Amortization $3.912M $3.480M
YoY Change 56.98% 71.6%
Cash From Operating Activities -$14.55M -$24.42M
YoY Change -10.57% 17.82%
INVESTING ACTIVITIES
Capital Expenditures $3.030M $3.560M
YoY Change -64.32% -135.56%
Acquisitions
YoY Change
Other Investing Activities $54.21M
YoY Change
Cash From Investing Activities $51.18M -$3.560M
YoY Change -702.66% -64.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 27.71M -410.0K
YoY Change 11.59% -100.56%
NET CHANGE
Cash From Operating Activities -14.55M -24.42M
Cash From Investing Activities 51.18M -3.560M
Cash From Financing Activities 27.71M -410.0K
Net Change In Cash 64.34M -28.39M
YoY Change 86848.65% -167.26%
FREE CASH FLOW
Cash From Operating Activities -$14.55M -$24.42M
Capital Expenditures $3.030M $3.560M
Free Cash Flow -$17.58M -$27.98M
YoY Change -29.01% 161.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1448305
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32548000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.29
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59526642
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44687635
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54544660
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44620900
CY2023Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://meiragtx.com/20230930#LeaseObligationsNonCurrent
CY2022Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://meiragtx.com/20230930#LeaseObligationsNonCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001735438
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48477209
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59597151
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38520
dei Entity Registrant Name
EntityRegistrantName
MeiraGTx Holdings plc
dei Entity Address Address Line1
EntityAddressAddressLine1
450 East 29th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
860-7985
dei Security12b Title
Security12bTitle
Ordinary Shares,$0.00003881 par value per share
dei Trading Symbol
TradingSymbol
MGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63597151
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63365000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115516000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22398000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21334000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6997000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8133000
CY2023Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
10013000
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7689000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
758000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1667000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
103531000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
154339000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111880000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109266000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1140000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1335000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
732000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
742000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1038000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1421000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1402000
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
6326000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
6326000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17446000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20109000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
23680000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24718000
CY2023Q3 us-gaap Assets
Assets
267194000
CY2022Q4 us-gaap Assets
Assets
318237000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
20773000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16616000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28251000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39818000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4092000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3884000
CY2023Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
7922000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
15123000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2476000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6631000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
63514000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82072000
CY2023Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
23191000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
27436000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14256000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17331000
CY2023Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2319000
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2179000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
184000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
186000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
71844000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
71033000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
262000
CY2023Q3 us-gaap Liabilities
Liabilities
175308000
CY2022Q4 us-gaap Liabilities
Liabilities
200499000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00003881
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00003881
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1288327750
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1288327750
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59597151
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48477209
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
659170000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
581893000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7160000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6047000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-574446000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470204000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
91886000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117738000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
267194000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
318237000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5103000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4816000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11977000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21208000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10009000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10762000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35169000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27856000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16862000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70115000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63960000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
37865000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
27624000
us-gaap Operating Expenses
OperatingExpenses
105284000
us-gaap Operating Expenses
OperatingExpenses
96508000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32762000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22808000
us-gaap Operating Income Loss
OperatingIncomeLoss
-93307000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75300000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8677000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-12838000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2915000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25911000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
523000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
288000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1723000
us-gaap Investment Income Interest
InvestmentIncomeInterest
345000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3381000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1892000
us-gaap Interest Expense
InterestExpense
9796000
us-gaap Interest Expense
InterestExpense
2051000
CY2022Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-34000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
53000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
615000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-44297000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37284000
us-gaap Net Income Loss
NetIncomeLoss
-104242000
us-gaap Net Income Loss
NetIncomeLoss
-102302000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6007000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8772000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1113000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18062000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38290000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28512000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103129000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84240000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44297000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37284000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104242000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-102302000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.29
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59526642
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44687635
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54544660
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44620900
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117738000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5201000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2353000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30364000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
90222000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7271000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
4003000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57947000
CY2023Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
209000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2541000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29581000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
123527000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6765000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
116000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6007000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-44297000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
91886000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185401000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4996000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1933000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31045000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
161285000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7303000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7357000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-33973000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
141972000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6937000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8772000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
2273000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37284000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
122670000
us-gaap Profit Loss
ProfitLoss
-104242000
us-gaap Profit Loss
ProfitLoss
-102302000
us-gaap Share Based Compensation
ShareBasedCompensation
20756000
us-gaap Share Based Compensation
ShareBasedCompensation
21818000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2915000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25911000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9818000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6231000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-153000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-85000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-89000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
38000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
130000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
125000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
809000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
170000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
53000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
615000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
198000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
2150000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1212000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2838000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2283000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-6518000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-898000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-578000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
15000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
111000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5393000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8628000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-13917000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
944000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1593000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11977000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21208000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90818000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56831000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17144000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36471000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17144000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36471000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
192000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1519000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2774000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
61950000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4119000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
75000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2051000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56312000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70367000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-51650000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-22935000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
537000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-62000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115516000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137703000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64403000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114706000
us-gaap Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
2941000
us-gaap Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
7598000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1793000
us-gaap Increase Decrease In Asset Retirement Obligations
IncreaseDecreaseInAssetRetirementObligations
8000
mgtx Issuance Of Shares In Connection With Notes Payable
IssuanceOfSharesInConnectionWithNotesPayable
2273000
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
209000
us-gaap Interest Paid Net
InterestPaidNet
9965000
us-gaap Interest Paid Net
InterestPaidNet
165000
mgtx No.Of Programs In Clinical Development
No.OfProgramsInClinicalDevelopment
6
mgtx No.Of Distinct Areas Of Unmet Medical Need
No.OfDistinctAreasOfUnmetMedicalNeed
3
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-574400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90800000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, the accounting for research and development costs, share-based compensation, valuation of warrants, leases, asset retirement obligations and tax incentive receivable.</p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63365000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115516000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1038000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64403000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115516000
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2179000
CY2021Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2081000
us-gaap Asset Retirement Obligation Liabilities Incurred
AssetRetirementObligationLiabilitiesIncurred
8000
mgtx Amortization Of Interest On Asset Retirement Obligation
AmortizationOfInterestOnAssetRetirementObligation
130000
mgtx Amortization Of Interest On Asset Retirement Obligation
AmortizationOfInterestOnAssetRetirementObligation
125000
us-gaap Asset Retirement Obligation Foreign Currency Translation Gain Loss
AssetRetirementObligationForeignCurrencyTranslationGainLoss
10000
us-gaap Asset Retirement Obligation Foreign Currency Translation Gain Loss
AssetRetirementObligationForeignCurrencyTranslationGainLoss
-133000
CY2023Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2319000
CY2022Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2081000
CY2023Q3 us-gaap Noncurrent Assets
NoncurrentAssets
154878000
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
156170000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11867971
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9288778
CY2023Q3 us-gaap Equity Method Investment Quoted Market Value
EquityMethodInvestmentQuotedMarketValue
6326000
CY2023Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
6665000
CY2023Q3 mgtx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
10827000
CY2022Q4 mgtx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
13041000
CY2023Q3 mgtx Accrued Research And Development
AccruedResearchAndDevelopment
4735000
CY2022Q4 mgtx Accrued Research And Development
AccruedResearchAndDevelopment
7400000
CY2023Q3 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
2898000
CY2023Q3 mgtx Accrued Liabilities Accrued Compensation And Benefits
AccruedLiabilitiesAccruedCompensationAndBenefits
2593000
CY2022Q4 mgtx Accrued Liabilities Accrued Compensation And Benefits
AccruedLiabilitiesAccruedCompensationAndBenefits
4326000
CY2023Q3 mgtx Accrued Liabilities Accrued Manufacturing Costs Expense
AccruedLiabilitiesAccruedManufacturingCostsExpense
2447000
CY2022Q4 mgtx Accrued Liabilities Accrued Manufacturing Costs Expense
AccruedLiabilitiesAccruedManufacturingCostsExpense
732000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1773000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9600000
CY2023Q3 mgtx Accrued Consulting Expenses
AccruedConsultingExpenses
1468000
CY2022Q4 mgtx Accrued Consulting Expenses
AccruedConsultingExpenses
3093000
CY2023Q3 mgtx Accrued Expenses Incurred In Connection With Fixed Assets
AccruedExpensesIncurredInConnectionWithFixedAssets
1278000
CY2022Q4 mgtx Accrued Expenses Incurred In Connection With Fixed Assets
AccruedExpensesIncurredInConnectionWithFixedAssets
694000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
232000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
932000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28251000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39818000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6858409
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.03
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1591840
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
142577
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.90
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8307672
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5484586
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M13D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
790
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
790
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2800000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2800000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12500000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
13600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.07
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7053000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6937000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20756000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21818000
mgtx Excess Tax Benefit From Share Based Compensation Operating Activities1
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
0
mgtx Excess Tax Benefit From Share Based Compensation Operating Activities1
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4000000.0
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
274000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
257000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
274000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
257000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1371000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1311000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
40000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
CY2023Q3 us-gaap Lease Cost
LeaseCost
1685000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1607000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
838000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
825000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
us-gaap Variable Lease Cost
VariableLeaseCost
838000
us-gaap Variable Lease Cost
VariableLeaseCost
826000
us-gaap Operating Lease Cost
OperatingLeaseCost
4103000
us-gaap Operating Lease Cost
OperatingLeaseCost
3986000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
119000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
115000
us-gaap Lease Cost
LeaseCost
5060000
us-gaap Lease Cost
LeaseCost
4927000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
18348000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21215000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
23680000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24718000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P175Y1M6D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P175Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1407000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1309000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
11000
us-gaap Operating Lease Payments
OperatingLeasePayments
4233000
us-gaap Operating Lease Payments
OperatingLeasePayments
4044000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1793000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1409000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5472000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5436000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5169000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1844000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
2876000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22206000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3858000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
18348000
CY2023Q3 mgtx Number Of New Material Commitments
NumberOfNewMaterialCommitments
0

Files In Submission

Name View Source Status
0001558370-23-018916-index-headers.html Edgar Link pending
0001558370-23-018916-index.html Edgar Link pending
0001558370-23-018916.txt Edgar Link pending
0001558370-23-018916-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgtx-20230930.xsd Edgar Link pending
mgtx-20230930x10q.htm Edgar Link pending
mgtx-20230930xex31d1.htm Edgar Link pending
mgtx-20230930xex31d2.htm Edgar Link pending
mgtx-20230930xex32d1.htm Edgar Link pending
mgtx-20230930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
mgtx-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mgtx-20230930_lab.xml Edgar Link unprocessable
mgtx-20230930_def.xml Edgar Link unprocessable
mgtx-20230930_pre.xml Edgar Link unprocessable
mgtx-20230930x10q_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending